Last reviewed · How we verify

NCT06606067: GENDOLCAT3

Duloxetine to Prevent Chronic Postsurgical Pain After Inguinal Hernia Repair in Patients at High Risk

Active, enrolled Phase 3 Last updated 20 September 2024
What this trial tests

Phase 3 trial testing Duloxetine in Chronic Post-surgical Pain in 294 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
3 September 2024
Primary endpoint
31 July 2026
31 December 2026

Quick facts

Lead sponsorParc de Salut Mar
PhasePhase 3
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment294
Start date3 September 2024
Primary completion31 July 2026
Estimated completion31 December 2026
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Parc de Salut Mar — full company profile →

Who can join

18 and older, male only, with Chronic Post-surgical Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The clinical trial will be conducted in 14 Spanish hospitals. It is estimated, based on our previous studies, that 2855 patients scheduled for elective inguinal hernia surgery will have to be assessed to detect patients with ≥ 27% level of risk for Chronic Post-Surgical Pain (CPSP). These high-risk patients will be randomized to 2 treatment groups: one will receive duloxetine for 2 weeks prior to surgery and 1 week after surgery (intervention group) and the other the placebo (control group) during the same periods. The primary outcome will be a ≥ 50% decrease in the CPSP incidence in the intervention group compared to the placebo group, 4 months after surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Duloxetine

Trials testing the same drug.

Other recruiting trials for Chronic Post-surgical Pain

Currently open trials in the same condition.

Other Parc de Salut Mar trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06606067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing